Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference Patch

NCT00791856 | Completed Phase 1

• 1 other identifier: 2007016
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 4

Brief Summary

This is an open-label, multiple-dose, randomized, two-period crossover bioequivalence study in approximately 110 surgically or naturally postmenopausal women on stable hormone therapy (i.e., estrogen for surgically postmenopausal women or a continuous regimen of estrogen plus progestin for naturally postmenopausal women) restricted to approved oral or transdermal regimens only, or not on concomitant hormone therapy.

Conditions

Healthy

Outcome Measures

Primary Outcomes (1)

• Bioequivalence of two testosterone patches based on baseline-corrected (AUCτ) and baseline-corrected maximum serum concentrations of total testosterone and free testosterone at steady-state

  12 days

Study Arms (2)

1

ACTIVE COMPARATOR

28 cm2 testosterone patch

Drug: testosterone

2

EXPERIMENTAL

14 cm2 testosterone patch

Drug: testosterone

Interventions

testosterone DRUG

28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used

1

Eligibility Criteria

• Age: 20 Years - 70 Years
• Sex: female
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• be a surgically postmenopausal female between 20 and 70 years of age who had a hysterectomy and bilateral oophorectomy at least 6 months prior to screening, or be a healthy naturally postmenopausal female between 50 and 70 years of age who had experienced amenorrhea for at least 12 months prior to screening;
• be in good general health based on medical history, physical examination, and laboratory evaluation;
• have had a mammogram, with no clinically significant abnormalities, within the preceding 12 months in subjects \> 40 years of age;
• be on a stable dose of approved hormone therapy restricted to oral or transdermal regimens (vaginal products are not acceptable) for a period of at least 12 weeks prior to screening:
• estrogen only for surgically postmenopausal women, or
• estrogen only for naturally postmenopausal women who have been hysterectomized, or
• a continuous regimen of estrogen plus progestin for naturally postmenopausal women who have not been hysterectomized
• or not be on any hormone therapy (having stopped hormone therapy at least 12 weeks prior to screening;

You may not qualify if:

• have any uncontrolled acute diseases or had a major surgical operation requiring hospitalization within 1 month of screening;
• have uncontrolled or chronic diseases, such as hypertension (with diastolic blood pressure \> 95 mm Hg on medication), systemic lupus erythematosus, or rheumatoid arthritis;
• have a history of myocardial infarction, bypass surgery, stroke, pulmonary embolism, or deep vein thrombosis;
• have a history of cancer within the last 5 years (except for basal cell carcinoma with a documented 6 month remission), abnormal vaginal bleeding, or tuberculosis;
• have uncontrolled diabetes mellitus with HbA1C \> 7.5% (Note: only subjects who have diabetes mellitus or a fasting serum glucose level at the screening visit above the laboratory's upper limit of normal for the reference range will have HbA1C tested prior to randomization.);
• have any abnormal clinical laboratory values at screening assessed as clinically significant by the Investigator;
• have a serum thyroid stimulating hormone (TSH) value outside the normal laboratory range, confirmed by free T4 levels outside the normal laboratory range;
• have current severe dermatological problems (e.g., severe or cystic acne), including concomitant skin disease or a history of drug-induced contact dermatitis;
• have participated in a cumulative irritation test within the past 12 weeks, or have a known or suspected hypersensitivity or allergy to any transdermal systems including components of the patches used in this study;
• currently use or have a history of any androgen treatment within 6 months prior to screening, or use dehydroepiandrosterone 25 mg per day, or St. John's Wort within 4 weeks prior to baseline. Due to the large number of herbal remedies available, all other herbal supplements will be reviewed by the Sponsor during screening;

Sponsors & Collaborators

• Warner Chilcott: lead

Study Sites (4)

Antonio Pizarro, MD

Fort Myers, Florida, 33901, United States

Location

Maria J Gulierrez, MD

Miramar, Florida, 33025, United States

Location

David R Mathews, MD

Overland Park, Kansas, 66211, United States

Location

Robert J Schwab, MD

Omaha, Nebraska, 68154, United States

Location

MeSH Terms

Interventions

Testosterone

Intervention Hierarchy (Ancestors)

Androstenols; Androstenes; Androstanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Testosterone Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Study Officials

• Angela X Qu, MD, MS

  Procter and Gamble

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 14, 2008
• First Posted: November 17, 2008
• Study Start: July 1, 2007
• Primary Completion: May 1, 2008
• Study Completion: May 1, 2008
• Last Updated: April 17, 2013

Record last verified: 2013-04

Locations

US (4)